From the past week, we highlight: 1) we lowered our target price in Investor to SEK320 following a 9% write-down of Patricia Industries in its Q1 report; 2) we reduced our target price in Kinnevik to SEK100 to reflect macroeconomic headwinds, but remain positive ahead of Cristina Stenbeck’s return as chair; 3) we cut our VEF target price to SEK2.5 on FX movements and see re-rating potential from e.g. ongoing buybacks; and 4) we lowered our target price in Flerie to SEK57 given worsening funding ...
We expect a muted Q1 EBITA of EUR33m, as seasonality weakens the results along with a slowdown in sales to new markets for Collection. We have cut our 2026–2027e EPS by 2% on adjustments to margins and order backlog. We have not heard any announcements regarding upcoming DRS’ status during the quarter. We reiterate our SELL and NOK120 target price.
The recent announcement of the application of trade tariffs by the Trump administration led to a sharp correction in oil prices amidst fears of an economic slowdown as a result of a full-blown trade war. We are adopting a more cautious scenario, with oil prices now expected to reach $ 67/b for 2025, $ 65/b for 2026 and $ 67/b in the longer term. Our 2025-2030 capex scenario has been lowered by 5% and our EPS expectations by 13% on average over 2025-2027, whilst our target prices have been lowere...
La récente annonce de mise en place de droits de douanes par l’administration Trump a entraîné une vive correction des cours du pétrole sur fond de crainte de ralentissement économique à la suite d’une véritable guerre commerciale. Nous adoptons un scenario plus prudent avec un baril désormais attendu respectivement à 67 $ sur2025, 65 $ 2026 et 67 $ sur le LT. Notre scénario de Capex 2025/30 a été abaissé de 5% et nos attentes de BPA de 13% en moyenne sur 2025/27 et nos OC de 10%. Nous privilégi...
From the past week, we highlight: 1) we are encouraged by the return of Cristina Stenbeck as chair of Kinnevik, and believe it could result in a lower discount to NAV; 2) VEF completed a milestone partial exit of Juspay at a 37% IRR, putting it on track to pay down debt and repurchase shares at a 50% discount to NAV in the near term; and 3) for Industrivärden, we recently reiterated our HOLD and lowered our target price to SEK345 (400), as we see risk to the earnings outlook of its portfolio com...
From the past week, we highlight: 1) we expect FX and multiples headwinds to weigh heavily on Kinnevik’s Q1 report; 2) VEF’s NAV looks set to grow by low single digits QOQ in USD terms; and 3) Industrivärden is due to report Q1 results next week, ahead of which we highlight a more attractive near-term investment story in its main owner Lundbergs.
From the past week, we highlight: 1) with Q1 coming to a close, we highlight valuation trends YTD for Investor, Kinnevik and Latour; 2) Klarna’s prospective IPO would have both direct and indirect effects on Swedish investment companies; and 3) Flerie is set to take Toleranzia private in an all-shares deal.
From the past week, we highlight: 1) Investor-owned Advanced Instruments agreed to acquire Nova Biomedical for USD2.2bn, creating Investor’s second-largest unlisted holding; 2) Svolder reported Q2 2024/25 NAV up 10% QOQ, outperforming the CSRX at 5%; 3) we see 24% NTM NAV growth potential in Bure’s portfolio; and 4) VNV further postponed its proposed USD83m sale of Gett.
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.